-
2026-10-28
IND Approval: GenSci136 Advances into Sj?gren's SyndromeLearn More
-
2026-10-22
Phase 3 trial in China successfully confirms ACARIZAX? safety and efficacy in patients with house dust mite allergyLearn More
-
2026-10-10
GenSci's Oncology Innovation: NDA Approval Secured for Prostate CancerLearn More
-
2026-10-09
GenSci's Two Innovations Received IND Clearance from NMPALearn More
-
2026-09-03
GenSci Showcases Innovation at CPHI Korea 2026Learn More
-
2025-12-02
A Leading Force in Innovation:
GenSci Earns Dual Recognition as Global Innovator & 2025 China Pharma Top 100Learn More
-
2025-10-24
GenSci Invites You to Meet Us at CPHI FRANKFURT 2025Learn More
-
2025-10-24
GenSci Announces Positive Phase II Results for GS1-144 Tablets in Chinese Postmenopausal Women with Moderate-to-Severe VMSLearn More
-
2025-10-13
GenSci Advances Women's Health with the Approval of Two Key ProductsLearn More
-
2025-10-09
From Long-acting Growth Hormone to Medical Devices: GenPEG Advances its High-purity ExpertiseLearn More
-
2025-09-18
GenSci Partners with Allergy Immunotherapy Leader ALK to Bring Innovative AIT Solutions for Chinese PatientsLearn More